NanoViricides, Inc. (NASDAQ:NNVC) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 11/10/2025 at 14:35, 24 days 14 hours ago

NanoViricides Granted Approval for Phase II Trial of NV-387 for MPox Treatment

NanoViricides NV-387 Clinical Trials Antiviral Drug Mpox
PRESS RELEASE

published on 11/10/2025 at 14:30, 24 days 14 hours ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NanoViricides, Inc. receives approval to start Phase II Clinical Trial of NV-387 for MPox treatment in the DRC. NV-387 shows promise as a broad-spectrum antiviral drug

NanoViricides NV-387 Phase II Clinical Trial Broad-spectrum Antiviral MPOX Treatment
BRIEF

published on 11/05/2025 at 14:35, 29 days 14 hours ago

NanoViricides Prepares for Critical Shareholders Meeting Amidst Rising MPox Concerns

NanoViricides NV-387 Clinical Trials Antiviral Drugs Mpox
PRESS RELEASE

published on 11/05/2025 at 14:30, 29 days 14 hours ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway

NV-387 Clinical Trials NanoViricides Inc. Annual Shareholders Meeting Mpox Clade I
BRIEF

published on 11/03/2025 at 14:35, 1 month 1 day ago

NanoViricides to Present at Spartan Capital Investor Conference 2025

NanoViricides NV-387 Clinical Trials Antiviral Drugs Spartan Capital Conference
PRESS RELEASE

published on 11/03/2025 at 14:30, 1 month 1 day ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing

NanoViricides NV-387 Clinical Trial Antiviral Drug Spartan Capital Investor Conference
BRIEF

published on 10/29/2025 at 13:50, 1 month 6 days ago

NV-387: A Promising Antiviral Agent for Measles

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Treatment
PRESS RELEASE

published on 10/29/2025 at 13:45, 1 month 6 days ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus
BRIEF

published on 10/27/2025 at 13:50, 1 month 8 days ago

NanoViricides Set to Present at PODD 2025 Conference

NanoViricides NV-387 Biotechnology Clinical Trials Antiviral Drug
PRESS RELEASE

published on 10/27/2025 at 13:45, 1 month 8 days ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
NanoViricides, Inc. to present at PODD 2025 Conference with focus on revolutionary broad-spectrum antiviral drugs in development for various viral infections

Respiratory Viral Infections NV-387 Antiviral Drugs NanoViricides, Inc. PODD 2025 Conference

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 50 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 55 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 25 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 20 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 25 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 55 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 35 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 10 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 15 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 25 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 40 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 41 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 24 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE